ClinicalTrials.gov record
Terminated Phase 2 Interventional

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00250861

Public ClinicalTrials.gov record NCT00250861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 9:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for CD20 Positive Aggressive Non-Hodgkin's Lymphoma Following High Dose Therapy With Autologous PBSC Rescue

Study identification

NCT ID
NCT00250861
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
US Oncology Research
Industry
Enrollment
110 participants

Conditions and interventions

Interventions

  • Aldesleukin Drug
  • Rituximab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2005
Primary completion
Jul 31, 2007
Completion
Jul 31, 2007
Last update posted
Apr 20, 2008

2005 – 2007

United States locations

U.S. sites
21
U.S. states
9
U.S. cities
21
Facility City State ZIP Site status
Rocky Mountain Cancer Center-Midtown Denver Colorado 80218
Hematology Oncology Associates of IL Chicago Illinois 60611
Cancer Care & Hematology Specialists of Chicagoland Niles Illinois 60714
Minnesota Oncology Hematology, PA Minneapolis Minnesota 55404
Kansas City Cancer Centers-Central Kansas City Missouri 64111
Greater Dayton Cancer Center Kettering Ohio 45409
Cancer Centers of the Carolinas Greenville South Carolina 29615
Texas Cancer Center Arlington Texas 76014
Texas Cancer Center at Medical City Dallas Texas 75230
El Paso Cancer Treatment Ctr El Paso Texas 79915
San Antonio Tumor & Blood Clinic Fredericksburg Texas 78624
Texas Oncology, PA Garland Texas 75042
Longview Cancer Center Longview Texas 75601
Tyler Cancer Center Tyler Texas 75702
Fairfax Northern VA Hem-Onc PC Fairfax Virginia 22031
Virginia Oncology Associates Norfolk Virginia 23502
Onc and Hem Associates of SW VA, Inc. Salem Virginia 24153
Puget Sound Cancer Center-Edmonds Edmonds Washington 98026
Pudget Sound Cancer Center-Seattle Seattle Washington 98133
Cancer Care Northwest-North Spokane Washington 99218
Yakima Valley Mem Hosp/North Star Lodge Yakima Washington 98902

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00250861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 20, 2008 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00250861 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →